Dr. Zisi Fotev appointed as Vice President of Business Development of atugen Aktiengesellschaft

Berlin, Germany (PROTEXT) - atugen Aktiengesellschaft todayannounced the appointment of Dr. Zisi Fotev to the position ofthe Vice President of Business Development. He relocated toatugen from his former position at Merck, Darmstadt, as Head ofLicensing and Strategic Alliances in the pharmaceutical division. His responsibilities at atugen will include directing atugen'sbusiness development activities, corporate development andintellectual property. These activities will includeresponsibility for all existing and future corporatecollaborations. Dr. Fotev received a BA of Science in Pathology & Microbiologyin 1983 at the University of Western Australia, Perth. In 1991he received his Ph.D. in Medical Physiology at the University ofTübingen, Germany. He joined Merck KgA, Darmstadt, Germany in1991 as the Head of Atherosclerosis & Restenosis Labs. andstarted his business development career in 1997. He accomplisheda number of successful deals at Merck including acquisitions ofLexigen, the negotiation of in-licensing technologies andproducts, and the formation of strategic alliances. With Dr. Fotev on board, atugen successfully achieved theformation of a full management team. His appointment is at animportant phase due to the increasing awareness of atugen'stechnology and potential increase in collaborations. Atugen AG is a German biotechnology company with itsheadquarters in Berlin, and a subsidiary in Boulder, Colorado,USA. Using GeneblocsTM Atugen discovers and validatespharmaceutical targets. Atugen's mission is to provide itspharmaceutical partners with cost-effective, high throughputtarget analysis, plus in vitro and in vivo target validation toaccelerate the drug development process. Atugen's currentcollaborations include Roche Bioscience, Chiron Corporation,Glaxo-Wellcome, Bayer, Millenium, Boehringer Ingelheim, AstraZeneca, Parke Davis and Schering AG through its US affiliate,Berlex Pharmaceutical Corporation. The atugen website isavailable at www.atugen.com ots Original Text Service: atugenAktiengesellschaft Internet: http://www.newsaktuell.de Contact:Dr. Jörg Pötzsch atugen Aktiengesellschaft Robert-Rössle-Str. 1013125 Berlin Phone: +49 30 9489 2700

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT